Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.

Daiichi Sankyo and AstraZeneca’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Adding adjuvant pertuzumab to standard adjuvant chemotherapy and trastuzumab improved overall survival at 11 years of follow-up in patients with early human epidermal growth factor receptor 2 ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

Investigator-assessed PFS demonstrated a median PFS of 40.7 months for ENHERTU plus pertuzumab compared to 20.7 months for THP (HR 0.49; 95% CI 0.39-0.61; nominal p-value <0.00001). Confirmed ...

Investigator-assessed PFS demonstrated a median PFS of 40.7 months for ENHERTU plus pertuzumab compared to 20.7 months for THP (HR 0.49; 95% CI 0.39-0.61; nominal p-value <0.00001). Confirmed ...